Multidisciplinary Cutaneous Lymphoma Clinic
Leadership and Excellence in Patient Care and Research
Mission
To provide excellence in patient care and leadership in scientific investigation of cutaneous lymphomas that will lead to greater knowledge and the development of new therapies to improve the survival and the quality of life of our patients.
The Stanford Multidsciplinary Cutaneous Lymphoma team offers expert treatment for patients with cutaneous lymphomas, including mycosis fungoides, Sezary syndrome, CD30+ lymphoproliferative disorders (lymphomatoid papulosis and anaplastic large cell lymphoma), subcutaneous panniculitis-like T-cell lymphoma, gamma-delta T-cell lymphoma, CD8+ aggressive epidermotropic T-cell lymphoma, NK/T-cell lymphoma, other unspecified cutaneous peripheral T-cell lymphomas, and cutaneous B-cell lymphomas. Our physicians subspecialize in treating these types of cancers, and have extensive expertise in handling the most complicated cases. Care among specialists is tightly integrated.
Read more about the Stanford Cutaneous Lymphoma Program (pdf) More>>
In the News
- Researchers find mutations that contribute to rare blood cancer - Researchers at the Stanford University School of Medicine have identified a group of mutations responsible for many cases of a rare immune cell cancer called cutaneous T-cell lymphoma.
- The rarest of rashes - Curing the skin's rogue cancer - Youn Kim, MD. and members of the multidisciplinary cutaneous lymphoma team, their research and clinical care were featured in this Stanford Medicine Magazine Summer 2015 issue.
What's New
- New NCCN Practice Guidelines in Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorder
1/2016- Newly released National Comprehensive Cancer Network (NCCN) Practice Guidelines for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorder is now available (see links to pdf below).
- Updated NCCN Practice Guidelines in Mycosis Fungoides/Sezary Syndrome and Cutaneous B-cell Lymphoma are available.
The National Comprehensive Cancer Network (NCCN) is an alliance of 21 of the world’s leading cancer centers (see list below) dedicated to improving the quality and effectiveness of care provided to patients with cancer. NCCN institutions work together to provide physicians and patients with up-to-date management guidelines that would lead to better care and improved quality of life for cancer patients. The development of the NCCN practice guidelines are based on available scientific evidence integrated with the experience and judgment of the clinical experts in the alliance. These cancer guidelines are utilized by clinicians worldwide and serve as an important standard-of-care resource. The NCCN institutions experts have pioneered and lead the concept of multidisciplinary team approach to patient care and believe that the best cancer management is the result of integration of programs in clinical care, research, and education.
For the first time in NCCN history, a practice guideline in mycosis fungoides/Sezary syndrome (MF/SS) and primary cutaneous B-cell lymphoma (CBCL) have been developed and is available on the NCCN website. Again, these guidelines embody the practice patterns in the 21 expert institutions in the NCCN alliance and integrates available scientific evidence in the management of patients with MF/SS and CBCL. The current guideline has been updated this year and includes the revised staging system and updated recommendation for diagnosis and staging evaluations. The treatment recommendations are stratified by clinical stage and other key prognostic factors. In a given clinical stage, available treatments are presented in an algorithmic fashion as primary treatment options and choices for refractory or progressive disease. This MF/SS practice guideline will serve as an important standard-of-care resource not only for clinicians and patients, but also for medicare and other health insurance providers. Medicare and insurance carriers refer to the NCCN practice guidelines for approval and reimbursement of cancer treatments. Thus, the clinicians who follow the NCCN guidelines will increase the chance of receiving authorization and reimbursement for treatments in the care of our patients with MF/SS and CBCL. These guidelines will be updated as new treatments and scientific evidence are available that justify incorporating the information in clinical practice.
The next skin topic that will be addressed by the NCCN NHL panel is to develop a clinical practice guideline for the CD30+ lymphoproliferative disorders. Please visit the official NCCN website at “nccn.org” for more information about NCCN and its resources and activities. For MF/SS practice guidelines, please go to the “NCCN Clinical Practice Guidelines”, then click on “Non-Hodgkin’s Lymphomas”.
Youn H. Kim, MD
Member of the NCCN NHL Panel
Joanne and Peter Haas Jr. Professor for Cutaneous Lymphoma Research
Director of the Multidisciplinary Cutaneous Lymphoma Program
Stanford Cancer Institute, Stanford, California
- Review of the Treatment of Mycosis Fungoides and Sézary Syndrome: A Stage-Based Approach (~2MB PDF)
- NCCN Clinical Practice Guidlines in Oncology - Non-Hodgkin's Lymphomas v.4.2014 (PDF)
- NCCN Practice Guidelines in Oncology – Mycosis Fungoides/Sezary Syndrome v.1.2016 (PDF)
- NCCN Practice Guidelines in Oncology - Primary Cutaneous B-Cell Lymphoma v.1.2016 (PDF)
- NCCN Practice Guidelines in Oncology - Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders v.1.2016 (PDF)
- Slides of Dr. Youn Kim's recent presentation
- Slides of Dr. Youn Kim's recent presentation at the PDA Annual Meeting
- Slides of Dr. Youn Kim's recent presentations at the American Academy of Dermatology Annual Meeting
- Slides of Dr. Youn Kim's recent presentation at the Dana Farber/Brigham and Women's Cancer Center
